论文部分内容阅读
Vectors based on the human adenovirus subgroup C (ie type 2 and 5) have been used extensively in preclinical and clinical studies of gene therapy.These recombinant adenoviral vectors have been rendered replication-defective by deletion of E1 sequences and grown in E-1 complementing cell lines such as HEK293.To generate even more disable vectors,multiple essential genes (such as E4 and E2) or even all viral genes have been deleted.However,an important limitation of the use of Ad2-and Ad5-based vectors is that many individuals are immune to these viruses because of previous infection.